Agios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) will announce its earnings results before the market opens on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($1.56) per share for the quarter.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. The firm had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. Agios Pharmaceuticals had a negative net margin of 491.54% and a negative return on equity of 71.20%. The business’s revenue was down 66.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.64) EPS. On average, analysts expect Agios Pharmaceuticals to post $-6.44 EPS for the current fiscal year and $-5.66 EPS for the next fiscal year.
Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 57.96 on Wednesday. The company’s market capitalization is $2.79 billion. The firm has a 50-day moving average of $53.89 and a 200 day moving average of $50.36. Agios Pharmaceuticals, Inc. has a 12-month low of $35.84 and a 12-month high of $67.74.
COPYRIGHT VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/26/agios-pharmaceuticals-inc-agio-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Several research firms have recently issued reports on AGIO. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, June 11th. Finally, Cann reissued a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $62.88.
In related news, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $50.06, for a total transaction of $150,180.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $150,180. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total transaction of $95,895.60. Following the transaction, the director now directly owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,974 shares of company stock valued at $1,709,236. 10.55% of the stock is owned by corporate insiders.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.